NxStage Medical tops Wall Street's forecasts for both sales and losses, sending share prices up nearly 8% today.
NxStage Medical (NSDQ:NXTM) shares jumped nearly 8% today after the medical device company reported Wall-Street-beating results for the 4th quarter and 2012.
NxStage Medical touts its 3rd European regulatory win this month with CE Mark approval for its OneSite single needle dialysis technology.
Massachusetts medical device maker NxStage Medical (NSDQ:NXTM) is on a roll, notching its 3rd regulatory win this month with CE Mark approval in the European Union for its OneSite single needle for dialysis patients.
European Union regulators grant CE Mark approval to NxStage Medical's high-flow System 1 home hemodialysis technology, hard on the heels of its approval for nocturnal home dialysis across the pond.
NxStage Medical (NSDQ:NXTM) won CE Mark approval in Europe for its System 1 technology, which includes new high-flow capabilities to the portable hemodialysis system.
NxStage Medical CEO Jeff Burbank tells MassDevice.com about the medical device company's 'great step forward' as it plans to market its System 1 home hemodialysis device for nocturnal therapy in the European Union.
UPDATED Feb. 19, 2:00 p.m. with comments from NxStage CEO Jeff Burbank.
NxStage Medical notches CE Mark approval in the European Union for nocturnal use of its System 1 home hemodialysis device.
NxStage Medical (NSDQ:NXTM) said it won CE Mark approval in the European Union for its System 1 home hemodialysis device, saying it expects to begin marketing the device for that indication in the 2nd half of this year.
A Chinese man constructs a makeshift dialysis machine after he runs out of savings and can't afford the cost of clinical treatment.
A Chinese man has undergone 13 years of dialysis with a machine he built himself out old medical instruments and kitchen utensils, resorting to the makeshift treatment after he was no longer able to pay for his hospital bills.
Hu Songwen told reporters that 2 of his friends had died using their own makeshift dialysis systems, but he remains dedicated to his home therapy.
A spate of lawsuits across the country accuse Fresenius of deliberately concealing problems with its GranuFlo and Naturalyte products, alleging that the dialysis additives caused patients to die.
A spate of lawsuits accuse Fresenius Medical (NYSE:FMS) of deliberately concealing potentially fatal problems with a pair of since-recalled products used during dialysis.